生物样本库规模药物基因组学揭示辛伐他汀使用的遗传基础
研究在UK Biobank的7,649名非洲裔和326,214名欧洲裔无亲缘关系参与者中,将50个药物基因的单倍型与用药表型关联。在欧洲裔中发现NAT2代谢表型及活性评分与辛伐他汀使用相关,NAT2*1与NAT2*5比较的关联稳健于LDL-C浓度和多基因风险影响,且NAT2*1与辛伐他汀对LDL-C的交互效应在eMERGE-PGx队列中重复。提示检测NAT2等位基因可能有助于他汀治疗前评估LDL-C获益。
要点
- 在欧洲裔中,NAT2代谢表型及活性评分与辛伐他汀使用相关。
- NAT2*1与辛伐他汀对LDL-C的交互效应在eMERGE-PGx队列中重复。
- 检测NAT2等位基因可能辅助他汀治疗前LDL-C绝对风险降低评估。
核心结论
- NAT2位点变异与对他汀治疗更好的反应相关,检测NAT2等位基因可能有助于临床决策。
研究设计与样本
- 在UK Biobank的7,649名无亲缘非洲裔和326,214名无亲缘欧洲裔参与者中,用广义线性模型将50个基因的药物基因单倍型与265个(欧洲裔)和17个(非洲裔)用药表型关联。
主要发现
- 在欧洲裔中,NAT2代谢表型及活性评分与辛伐他汀使用相关。
- 与NAT2*5比较,NAT2*1剂量与辛伐他汀使用相关,该关联对LDL-C浓度效应稳健(NAT2*1 OR=1.07,95%CI:1.05-1.09,P=1.14×10^-8)。
- 该关联对LDL-C浓度多基因风险稳健(NAT2*1 OR=1.09,95%CI:1.04-1.14,P=2.26×10^-4)。
- NAT2*1与辛伐他汀使用对LDL-C浓度的交互效应(OR=0.957,95%CI:0.916-0.998,P=0.045)在eMERGE-PGx队列中重复(OR=0.987,95%CI:0.976-0.998,P=0.029)。
临床怎么用
- 检测NAT2等位基因可能有助于他汀治疗前评估LDL-C浓度的潜在获益(如绝对风险降低)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Studying drug-metabolizing enzymes, encoded by pharmacogenes, may inform biological mechanisms underlying the diseases for which a medication is prescribed. Until recently, pharmacogenes could not be studied at biobank scale. In 7,649 unrelated African-ancestry (AFR) and 326,214 unrelated European-ancestry (EUR) participants from the UK Biobank, we associated pharmacogene haplotypes from 50 genes with 265 (EUR) and 17 (AFR) medication use phenotypes using generalized linear models. In EUR, N-acetyltransferase 2 (NAT2) metabolizer phenotype and activity score were associated with simvastatin use. The dose of NAT2*1 was associated with simvastatin use when compared with NAT2*5 (the most common haplotype). This association was robust to effects of low-density lipoprotein cholesterol (LDL-C) concentration (NAT2*1 odds ratio (OR) = 1.07, 95% CI: 1.05-1.09, P = 1.14 × 10-8 ) and polygenic risk for LDL-C concentration (NAT2*1 OR = 1.09, 95% CI: 1.04-1.14, P = 2.26 × 10-4 ). Interactive effects between NAT2*1 and simvastatin use on LDL-C concentration (OR = 0.957, 95% CI: 0.916-0.998, P = 0.045) were replicated in the electronic Medical Records and Genomics Pharmacogenetic Sequencing Pilot (eMERGE-PGx) cohort (OR = 0.987, 95% CI: 0.976-0.998, P = 0.029). We used biobank-scale data to uncover and replicate an association between NAT2 locus variation and better response to statin therapy. Testing NAT2 alleles may be useful for making clinical decisions regarding the potential benefit (e.g., absolute risk reduction) in LDL-C concentration prior to statin treatment.
引用
- Wendt FR, Koller D, Pathak GA, et al. Biobank Scale Pharmacogenomics Informs the Genetic Underpinnings of Simvastatin Use. Clin Pharmacol Ther. 2021. PMID: 33837531. doi:10.1002/cpt.2260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。